Additionally, the inhibition of PLK1, a cell-cycle-related kinase, has been identified as a potential therapeutic target in clear cell renal cell carcinoma, further supporting the potential of combined mTOR and Chk1 inhibition in this context (199). The gene discussed is MTOR; the disease is clear cell renal carcinoma.